Latest Non Dilutive Funding News

Spacetalk Ltd has secured an $877k R&D tax refund for FY2025, more than doubling last year’s amount, underscoring its strategic pivot to software and a 20% growth in recurring revenue.

Pivotal Metals is ramping up exploration at its Belleterre projects in Quebec following a successful $5.4 million financing, targeting high-grade gold, copper, nickel, and PGM deposits with drilling planned for late 2025.

Elevra Lithium reports robust Q1 FY26 results with record production and a significant increase in lithium resources, advancing its brownfield expansion and multiple development projects.

Everest Metals has initiated a 2,500m drilling campaign at its Mt Dimer Taipan Gold Project to upgrade and extend its mineral resource ahead of mining operations scheduled for late 2025.

Nova Eye Medical reported a 20% year-on-year revenue increase in Q1 FY26, reaffirming its FY26 sales guidance and targeting breakeven EBITDA by June 2026 amid cautious commercial expansion.

Tryptamine Therapeutics has initiated the world’s first clinical trial of its IV-infused psilocin drug, TRP-8803, targeting Binge Eating Disorder, alongside a pioneering EEG biomarker collaboration and new funding.

Atlantic Lithium has finalized revised fiscal terms with the Ghanaian government for its Ewoyaa Lithium Project and awaits parliamentary ratification, while reporting strong exploration results in Côte d’Ivoire and securing significant funding agreements.

Arcadia Minerals has secured a binding farm-in agreement with Kaoko Metals for its Karibib Copper Gold Project, unlocking immediate cash and future equity incentives while advancing exploration partnerships across its Namibian portfolio.

Cadoux Limited has made significant progress in its High Purity Alumina (HPA) front-end engineering design and advanced the Minhub rare earths feasibility study, positioning itself strongly in the evolving critical minerals market.

International Graphite Limited has made significant strides in its global graphite strategy, signing a German joint venture and securing $3 million in US institutional funding to support its expanding mine-to-market operations.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug candidate NUZ-001 and strengthened its balance sheet with a $5.2 million capital raise. The company is now poised to enter the pivotal HEALEY ALS Platform Trial, marking a significant step forward in its neurodegenerative disease program.

Felix Gold Limited has made significant strides in transitioning its Treasure Creek project from exploration to operational readiness, positioning itself as a key domestic supplier of critical antimony for the U.S. market.